<p>防御性行业，如医疗保健，对收入投资者更具吸引力。这是因为该行业的公司在经济困难时期不太可能遭受重大业务中断，这意味着它们也不太可能削减分红。医疗需求与许多技术产品或服务不同，并不是可选的。果然，医疗保健行业拥有许多优秀的分红股票。让我们考虑两个可能为其股东带来终身回报（或更长时间）的公司：<strong>默克</strong>（MRK -0.43%）和 <strong>美敦力</strong>（MDT 0.92%）。</p>
<h2>1. 默克</h2>
<p>默克今年的表现不佳：公司的股价下跌了 4%。制药公司表现不佳的一个原因是投资者担心默克著名的癌症药物 Keytruda 可能面临竞争，而这款药物无疑是其最大的增长驱动力。<strong>Summit Therapeutics</strong> 是一家临床阶段的生物技术公司，正在开发一种名为 ivonescimab 的药物，可能在非小细胞肺癌（NSCLC）这一关键市场与 Keytruda 竞争。</p>
<p>此外，Keytruda 将在 2028 年失去在美国的专利独占权，届时将面临仿制药竞争。尽管如此，即使 ivonescimab 在此之前上市，Keytruda 的收入在 2028 年前仍应继续增长。美国食品药品监督管理局（FDA）已批准该药物用于多个适应症，而 ivonescimab 在 2028 年前大多数适应症上不会触及。默克还在研发该药物的皮下给药版本。该配方在 2028 年不会失去独占权，并且应该会取得一定的成功。</p>
<p>默克面临的逆风是制药公司常见的情况。这家医疗保健领导者能够生存并蓬勃发展数十年，正是因为其开发新药的能力。这是抵御竞争的最佳防御。而在这方面，默克仍应表现出色。公司的研发管线包含数十个项目。由于收购，默克还在扩展其管线。最近批准的 Winrevair，一种用于肺动脉高压的药物，源于对 Acceleron Pharma 的收购。</p>
<p>默克还与多家小型公司签订了多项合作协议，包括与 <strong>Moderna</strong> 合作开发个性化癌症疫苗。关键在于：过于关注与 Keytruda 相关的问题可能会导致投资者忽视整体情况。默克的道路上总会有逆风，但使公司能够持续发展的因素依然存在。该公司也有着稳健的分红记录。在过去十年中，其分红增加了 71%，目前提供的前瞻性收益率为 2.96%，高于 <strong>标准普尔 500</strong> 的平均水平 1.32%。</p>
<p>默克仍然是一个可靠的收入股票，值得持有。</p>
<h2>2. 美敦力</h2>
<p>美敦力是一家医疗设备专家，拥有罕见的分红记录。该公司连续 47 年增加分红。能够做到这一点需要强大的业务，而美敦力正是如此。它在多个类别中拥有数十种产品，并在全球 100 多个国家运营。这并不保证美敦力的表现特别好，但该公司有几个令人兴奋的长期机会。</p>
<p>其中一个机会在于其糖尿病护理部门，最近成为其最大的增长驱动力。美敦力在该领域的创新包括 MiniMed 780G，这是唯一一款具有餐食检测技术的胰岛素泵（它会根据患者的需求自动调整胰岛素水平）。全球有五亿成年人受到糖尿病的影响，因此迫切需要美敦力开发的这类产品。美敦力还在开发一种机器人辅助手术设备 Hugo 系统，这可能成为一个重要的长期推动力。</p>
<p><strong>Intuitive Surgical</strong> 主导着这个市场，但考虑到全球老龄化人口以及这将对医疗系统造成的需求增加，微创手术机器人系统将变得越来越重要。这些手术通常比开放手术切口更小，因此造成的伤疤和出血更少，恢复时间和住院时间也更短。Hugo 系统目前正在美国进行临床试验。</p>
<p>美敦力在最近几个季度的收入增长方面遇到了一些困难。然而，从长远来看，这家医疗巨头应该会恢复。美敦力应该会在几年内成为分红之王，并在此后继续增加分红。</p>

默克

<p>本文讨论了两只推荐用于长期被动收入的股息股票：默克和美敦力。尽管默克在其癌症药物 Keytruda 方面面临竞争，但其产品线强劲，过去十年股息增长了 71%。美敦力以其医疗设备而闻名，已连续 47 年提高股息，并专注于糖尿病护理和机器人辅助手术的增长。这两家公司在医疗保健行业的定位良好，使其对收入投资者具有吸引力</p>

<p>Defensive industries, like healthcare, are more attractive to income investors. That's because companies in this sector are less likely to suffer significant business disruptions in times of economic trouble, meaning they are also less likely to cut their payouts. Medical needs, unlike many technological products or services, aren't optional. Sure enough, the healthcare industry is home to many excellent dividend stocks. Let's consider two that could reward their shareholders for a lifetime (or more): <strong>Merck</strong>(MRK -0.43%) and <strong>Medtronic</strong>(MDT 0.92%).</p>
<div class="lb-trans"><p>防御性行业，如医疗保健，对收入投资者更具吸引力。这是因为该行业的公司在经济困难时期不太可能遭受重大业务中断，这意味着它们也不太可能削减分红。医疗需求与许多技术产品或服务不同，并不是可选的。果然，医疗保健行业拥有许多优秀的分红股票。让我们考虑两个可能为其股东带来终身回报（或更长时间）的公司：<strong>默克</strong>（MRK -0.43%）和 <strong>美敦力</strong>（MDT 0.92%）。</p>
</div><h2>1. Merck</h2>
<div class="lb-trans"><h2>1. 默克</h2>
</div><p>Merck isn't having a good year: The company's shares are down by 4%. One reason behind the drugmaker's poor performance is that investors are worried about potential competition for Keytruda, Merck's famous cancer drug, which is by far its biggest growth driver. <strong>Summit Therapeutics</strong>, a clinical-stage biotech, has a medicine in development called ivonescimab that could rival Keytruda in non-small cell lung cancer (NSCLC), one of its key markets.</p>
<div class="lb-trans"><p>默克今年的表现不佳：公司的股价下跌了 4%。制药公司表现不佳的一个原因是投资者担心默克著名的癌症药物 Keytruda 可能面临竞争，而这款药物无疑是其最大的增长驱动力。<strong>Summit Therapeutics</strong> 是一家临床阶段的生物技术公司，正在开发一种名为 ivonescimab 的药物，可能在非小细胞肺癌（NSCLC）这一关键市场与 Keytruda 竞争。</p>
</div><p>Furthermore, Keytruda will lose patent exclusivity in the U.S. in 2028 and then face generic competition. That said, Keytruda's revenue should continue growing until 2028 even if ivonescimab hits the market before. The Food and Drug Administration (FDA) has approved the medicine across scores of indications, most of which ivonescimab won't touch before 2028. Merck is also working on a subcutaneous version of the drug. This formulation won't lose exclusivity in 2028 and should be somewhat successful.</p>
<div class="lb-trans"><p>此外，Keytruda 将在 2028 年失去在美国的专利独占权，届时将面临仿制药竞争。尽管如此，即使 ivonescimab 在此之前上市，Keytruda 的收入在 2028 年前仍应继续增长。美国食品药品监督管理局（FDA）已批准该药物用于多个适应症，而 ivonescimab 在 2028 年前大多数适应症上不会触及。默克还在研发该药物的皮下给药版本。该配方在 2028 年不会失去独占权，并且应该会取得一定的成功。</p>
</div><p>Headwinds, such as the ones Merck is facing, are typical for pharmaceutical companies. The healthcare leader has survived and thrived for decades because of its ability to develop new medicines. That's the best defense against competition. And in that department, Merck should still excel. The company's pipeline features several dozen programs. It is also expanding it thanks to acquisitions. Its most-recent, brand-new approval of Winrevair, a medicine for pulmonary arterial hypertension, stemmed from the acquisition of Acceleron Pharma.</p>
<div class="lb-trans"><p>默克面临的逆风是制药公司常见的情况。这家医疗保健领导者能够生存并蓬勃发展数十年，正是因为其开发新药的能力。这是抵御竞争的最佳防御。而在这方面，默克仍应表现出色。公司的研发管线包含数十个项目。由于收购，默克还在扩展其管线。最近批准的 Winrevair，一种用于肺动脉高压的药物，源于对 Acceleron Pharma 的收购。</p>
</div><p>Merck also has several collaboration agreements with smaller companies, including <strong>Moderna</strong>, with which it is developing a personalized cancer vaccine. Here's the point: Focusing too much on Keytruda-related issues might cause investors to miss the forest from the trees. There will always be headwinds in Merck's way, but the things that have allowed the company to last as long as it has remained intact. The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a forward yield of 2.96%, higher than the <strong>S&amp;P 500</strong>'s average of 1.32%.</p>
<div class="lb-trans"><p>默克还与多家小型公司签订了多项合作协议，包括与 <strong>Moderna</strong> 合作开发个性化癌症疫苗。关键在于：过于关注与 Keytruda 相关的问题可能会导致投资者忽视整体情况。默克的道路上总会有逆风，但使公司能够持续发展的因素依然存在。该公司也有着稳健的分红记录。在过去十年中，其分红增加了 71%，目前提供的前瞻性收益率为 2.96%，高于 <strong>标准普尔 500</strong> 的平均水平 1.32%。</p>
</div><p>Merck remains a reliable income stock to hold onto for good.</p>
<div class="lb-trans"><p>默克仍然是一个可靠的收入股票，值得持有。</p>
</div><h2>2. Medtronic</h2>
<div class="lb-trans"><h2>2. 美敦力</h2>
</div><p>Medtronic, a medical-device specialist, has a rare dividend streak. The company has increased its payouts for 47 consecutive years. It takes a strong business to pull that off, and that's what Medtronic has. It boasts dozens of products across several categories and operates in more than 100 countries worldwide. That doesn't guarantee that Medtronic will perform particularly well, but the company has several exciting long-term opportunities.</p>
<div class="lb-trans"><p>美敦力是一家医疗设备专家，拥有罕见的分红记录。该公司连续 47 年增加分红。能够做到这一点需要强大的业务，而美敦力正是如此。它在多个类别中拥有数十种产品，并在全球 100 多个国家运营。这并不保证美敦力的表现特别好，但该公司有几个令人兴奋的长期机会。</p>
</div><p>One is within its diabetes care segment, which has been its biggest growth driver lately. Medtronic's innovations in the field include its MiniMed 780G, the only insulin pump with meal-detection technology (it automatically adjusts insulin levels based on patients' needs). With diabetes affecting half a billion adults worldwide, there is a dire need for precisely the kinds of products Medtronic develops. Medtronic is also developing a robotic-assisted surgery device, the Hugo system, that could prove to be an important long-term tailwind.</p>
<div class="lb-trans"><p>其中一个机会在于其糖尿病护理部门，最近成为其最大的增长驱动力。美敦力在该领域的创新包括 MiniMed 780G，这是唯一一款具有餐食检测技术的胰岛素泵（它会根据患者的需求自动调整胰岛素水平）。全球有五亿成年人受到糖尿病的影响，因此迫切需要美敦力开发的这类产品。美敦力还在开发一种机器人辅助手术设备 Hugo 系统，这可能成为一个重要的长期推动力。</p>
</div><p><strong>Intuitive Surgical</strong> dominates this market, but given the world's aging population and the increased demand that will place on health systems, the minimally invasive surgeries robot systems allow physicians to perform should become increasingly important. They typically involve less cutting off the skin than open surgeries, and hence less scaring and less bleeding, and shorter recovery times and hospital stays. The Hugo system is currently undergoing clinical trials in the U.S.</p>
<div class="lb-trans"><p><strong>Intuitive Surgical</strong> 主导着这个市场，但考虑到全球老龄化人口以及这将对医疗系统造成的需求增加，微创手术机器人系统将变得越来越重要。这些手术通常比开放手术切口更小，因此造成的伤疤和出血更少，恢复时间和住院时间也更短。Hugo 系统目前正在美国进行临床试验。</p>
</div><p>Medtronic has had some trouble growing its revenue at a good clip in recent quarters. However, over the long run, the healthcare giant should recover. Medtronic should become a Dividend King within a few years and continue growing its payouts long after.</p>
<div class="lb-trans"><p>美敦力在最近几个季度的收入增长方面遇到了一些困难。然而，从长远来看，这家医疗巨头应该会恢复。美敦力应该会在几年内成为分红之王，并在此后继续增加分红。</p>
</div>

两只适合终身被动收入的股息股票